Table 3– Lung function outcomes according to continued smoking or smoking cessation in pulmonary Langerhans’ cell histiocytosis patients who were current smokers at the time of diagnosis
Lung functionImprovementDeterioration
Continued smokingSmoking cessationContinued smokingSmoking cessation
Subjects30163016
Overall5 (17)5 (31)17 (56)8 (50)
FVC5 (17)4 (25)7 (23)2 (12.5)
FEV15 (17)3 (19)13 (43)4 (25)
DL,CO1/25 (4)1/13 (8)13/25 (52)4/13 (31)

  • Data are presented as n or n (%). n=46. The lung function parameters represent all patients, unless otherwise specified. For each parameter, changes of ≥10% in forced expiratory volume in 1 s (FEV1) or forced vital capacity (FVC), or of ≥15% in diffusing capacity of the lung for carbon monoxide (DL,CO) constituted improvement or deterioration. The overall lung function outcome was defined based on increases or decreases of ≥10% in FEV1 and/or FVC and/or of ≥15% in DL,CO. In case of discrepancies, the impaired parameter was used. p-values were not significant for any of the comparisons.